DUBLIN--(BUSINESS WIRE)--

Research and Markets (http://www.researchandmarkets.com/research/49mg4f/personalized_medic) has announced the addition of the "Personalized Medicine - A Strategic Analysis of Industry Trends, Technologies, Participants and Environment" report to their offering.

Personalized Medicine- A Strategic Analysis of Industry Trends, Technologies, Participants, and Environment by Kelly Scientific Publications is a comprehensive assessment of this developing industry thus far. This report tackles the growing market interest in personalized medicine (PM), pharmacogenomics, companion diagnostics and the associated market environment.

Individualized or personalized medicine aims to increase the efficacy of therapeutics via genetic testing and companion diagnostics. As we progress through the era of genomic medicine, patients will benefit by more effective therapies and less side effects. Developmental and diagnostic companies will benefit from lower discovery and commercialization costs and more specific market subtypes.

The average drug-to-market cost varies but is estimated at $500 million, however with the advent of personalized therapeutics and companion diagnostics this cost could be dramatically reduced. Only 30% of drugs recover the cost to market however personalized therapeutics and associated companion diagnostics will be more specific and effective thereby giving pharma/biotech companies a significant advantage to recuperate costs. Personalized medicine will reduce the frequency of adverse drug reactions and therefore have a dramatic impact on health economics.

Companies Mentioned:

- 23andMe

- Affymetrix

- Astex Pharmaceuticals

- Atossa Genetics

See more here:
Research and Markets: Personalized Medicine - A Strategic Analysis of Industry Trends, Technologies, Participants and ...

Comments are closed.